Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer.

Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas V, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.

Clin Cancer Res. 2019 Sep 23. pii: clincanres.1667.2019. doi: 10.1158/1078-0432.CCR-19-1667. [Epub ahead of print]

PMID:
31548343
2.

Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.

Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F.

Nat Commun. 2019 Jul 11;10(1):3055. doi: 10.1038/s41467-019-11044-9.

3.

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T.

Nature. 2019 May;569(7754):131-135. doi: 10.1038/s41586-019-1130-6. Epub 2019 Apr 17.

4.

Molecular subtypes of pancreatic cancer.

Collisson EA, Bailey P, Chang DK, Biankin AV.

Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220. doi: 10.1038/s41575-019-0109-y. Review.

PMID:
30718832
5.

Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma.

Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Anderson JM, Johansen JS, Hollingsworth MA, Yeh JJ, Collisson EA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00121. Epub 2018 Jan 16.

6.

Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.

Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH.

Fam Cancer. 2019 Apr;18(2):241-251. doi: 10.1007/s10689-018-0106-2.

PMID:
30267352
7.

Bringing Pancreas Cancer into the Lab.

Collisson EA.

Cancer Discov. 2018 Sep;8(9):1062-1063. doi: 10.1158/2159-8290.CD-18-0811.

8.

APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.

Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP.

Sci Transl Med. 2018 Aug 22;10(455). pii: eaas9668. doi: 10.1126/scitranslmed.aas9668.

PMID:
30135250
9.

Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.

Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA.

AJR Am J Roentgenol. 2018 Nov;211(5):1010-1019. doi: 10.2214/AJR.18.19602. Epub 2018 Jul 31.

PMID:
30063366
10.

Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma.

North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ.

Nat Commun. 2018 May 14;9(1):1894. doi: 10.1038/s41467-018-04008-y.

11.

Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.

Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK.

Oncologist. 2018 Sep;23(9):998-1003. doi: 10.1634/theoncologist.2017-0645. Epub 2018 Apr 5.

12.

Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS.

Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17.

13.

Advances in the Genetics and Biology of Pancreatic Cancer.

Aguirre AJ, Collisson EA.

Cancer J. 2017 Nov/Dec;23(6):315-320. doi: 10.1097/PPO.0000000000000286. Review.

PMID:
29189326
14.

Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW.

PLoS One. 2017 Oct 11;12(10):e0186551. doi: 10.1371/journal.pone.0186551. eCollection 2017.

15.

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.

Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA.

Cancer Res. 2017 Aug 15;77(16):4498-4505. doi: 10.1158/0008-5472.CAN-16-1944. Epub 2017 May 18.

16.

Pancreatic Cancer Genomics 2.0: Profiling Metastases.

Collisson EA, Maitra A.

Cancer Cell. 2017 Mar 13;31(3):309-310. doi: 10.1016/j.ccell.2017.02.014.

17.

Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field.

Collisson EA, Olive KP.

Cancer Res. 2017 Mar 1;77(5):1060-1062. doi: 10.1158/0008-5472.CAN-16-2452. Epub 2017 Feb 16.

18.

Stromal cues regulate the pancreatic cancer epigenome and metabolome.

Sherman MH, Yu RT, Tseng TW, Sousa CM, Liu S, Truitt ML, He N, Ding N, Liddle C, Atkins AR, Leblanc M, Collisson EA, Asara JM, Kimmelman AC, Downes M, Evans RM.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1129-1134. doi: 10.1073/pnas.1620164114. Epub 2017 Jan 17.

19.

The Authors Respond.

Chapman JS, Collisson EA, Taylor BS.

J Natl Compr Canc Netw. 2016 Mar;14(3):lxviii. No abstract available.

PMID:
27396027
20.

Election 2016: Voting on Variants.

Cho RJ, Collisson EA.

Cancer Discov. 2016 Jul;6(7):694-6. doi: 10.1158/2159-8290.CD-16-0559.

21.

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.

Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL.

Cancer Lett. 2016 Sep 28;380(1):144-52. doi: 10.1016/j.canlet.2016.06.017. Epub 2016 Jun 22.

PMID:
27343980
22.

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.

Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G; Cancer Genome Atlas Research Network, Artyomov MN, Schreiber R, Govindan R, Meyerson M.

Nat Genet. 2016 Jun;48(6):607-16. doi: 10.1038/ng.3564. Epub 2016 May 9.

23.

Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.

Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM.

Nat Med. 2016 May;22(5):497-505. doi: 10.1038/nm.4082. Epub 2016 Apr 18.

24.

Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".

Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS.

J Natl Compr Canc Netw. 2016 Mar;14(3):lxvi-lxviii. No abstract available.

PMID:
26957621
25.

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.

Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, Kermani BG, Eltoukhy H, Talasaz A.

PLoS One. 2015 Oct 16;10(10):e0140712. doi: 10.1371/journal.pone.0140712. eCollection 2015.

26.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.

27.

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18.

28.

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.

Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM.

Clin Cancer Res. 2016 Jan 1;22(1):61-8. doi: 10.1158/1078-0432.CCR-15-0979. Epub 2015 Aug 6.

29.

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Korkola JE, Collisson EA, Heiser M, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW.

PLoS One. 2015 Jul 16;10(7):e0133219. doi: 10.1371/journal.pone.0133219. eCollection 2015. Erratum in: PLoS One. 2017 Oct 11;12 (10 ):e0186551.

30.

Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.

Chapman JS, Asthana S, Cade L, Chang MT, Wang Z, Zaloudek CJ, Ueda S, Collisson EA, Taylor BS.

J Natl Compr Canc Netw. 2015 Jul;13(7):835-45.

PMID:
26150578
31.

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA.

Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun 24.

32.

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.

Nan X, Tamgüney TM, Collisson EA, Lin LJ, Pitt C, Galeas J, Lewis S, Gray JW, McCormick F, Chu S.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):7996-8001. doi: 10.1073/pnas.1509123112. Epub 2015 Jun 16.

33.

Erratum to: Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2015 May 12;16:95. doi: 10.1186/s13059-015-0658-5.

34.

Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.

Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW.

BMC Cancer. 2015 Mar 31;15:206. doi: 10.1186/s12885-015-1195-z.

35.

Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation.

Roy N, Malik S, Villanueva KE, Urano A, Lu X, Von Figura G, Seeley ES, Dawson DW, Collisson EA, Hebrok M.

Genes Dev. 2015 Mar 15;29(6):658-71. doi: 10.1101/gad.256628.114.

36.

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG.

Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.

37.

RB and Prognosis in Resected Lung Adenocarcinoma.

Collisson EA.

Clin Cancer Res. 2015 Jun 1;21(11):2418-20. doi: 10.1158/1078-0432.CCR-14-2931. Epub 2015 Feb 2.

38.

Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes.

Zheng CL, Wang NJ, Chung J, Moslehi H, Sanborn JZ, Hur JS, Collisson EA, Vemula SS, Naujokas A, Chiotti KE, Cheng JB, Fassihi H, Blumberg AJ, Bailey CV, Fudem GM, Mihm FG, Cunningham BB, Neuhaus IM, Liao W, Oh DH, Cleaver JE, LeBoit PE, Costello JF, Lehmann AR, Gray JW, Spellman PT, Arron ST, Huh N, Purdom E, Cho RJ.

Cell Rep. 2014 Nov 20;9(4):1228-34. doi: 10.1016/j.celrep.2014.10.031. Epub 2014 Nov 20.

39.

RADIA: RNA and DNA integrated analysis for somatic mutation detection.

Radenbaugh AJ, Ma S, Ewing A, Stuart JM, Collisson EA, Zhu J, Haussler D.

PLoS One. 2014 Nov 18;9(11):e111516. doi: 10.1371/journal.pone.0111516. eCollection 2014.

40.

Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM.

Cell. 2014 Sep 25;159(1):80-93. doi: 10.1016/j.cell.2014.08.007.

41.

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA; Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM.

Cell. 2014 Aug 14;158(4):929-944. doi: 10.1016/j.cell.2014.06.049. Epub 2014 Aug 7.

42.

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):E748-57. doi: 10.1073/pnas.1320956111. Epub 2014 Feb 3.

43.

Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2013;14(10):R110. Erratum in: Genome Biol. 2015;16:95.

44.

Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling.

Nan X, Collisson EA, Lewis S, Huang J, Tamgüney TM, Liphardt JT, McCormick F, Gray JW, Chu S.

Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18519-24. doi: 10.1073/pnas.1318188110. Epub 2013 Oct 24.

45.

A robust prognostic signature for hormone-positive node-negative breast cancer.

Griffith OL, Pepin F, Enache OM, Heiser LM, Collisson EA, Spellman PT, Gray JW.

Genome Med. 2013 Oct 11;5(10):92. doi: 10.1186/gm496. eCollection 2013.

46.

The Cancer Genome Atlas Pan-Cancer analysis project.

Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM.

Nat Genet. 2013 Oct;45(10):1113-20. doi: 10.1038/ng.2764.

47.

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.

Trejo CL, Green S, Marsh V, Collisson EA, Iezza G, Phillips WA, McMahon M.

Cancer Res. 2013 Nov 1;73(21):6448-61. doi: 10.1158/0008-5472.CAN-13-0681. Epub 2013 Sep 9.

48.

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.

Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM.

Mol Cancer Ther. 2013 Oct;12(10):2213-25. doi: 10.1158/1535-7163.MCT-13-0104. Epub 2013 Aug 5.

49.

A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D.

Nat Med. 2013 May;19(5):619-25. doi: 10.1038/nm.3175. Epub 2013 Apr 14.

50.

Histology, anatomy, or geography? Exome sequencing begins to delineate somatic mutational differences in esophageal cancer.

Collisson EA, Cho RJ.

Cancer Discov. 2012 Oct;2(10):870-1. doi: 10.1158/2159-8290.CD-12-0393.

Supplemental Content

Loading ...
Support Center